Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
Status:
Withdrawn
Trial end date:
2020-09-22
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well itacitinib works in preventing graft versus host disease
in patients with blood disorders undergoing donor stem cell transplantation. A donor
transplantation uses blood-making cells from a family member or unrelated donor to remove and
replace abnormal blood cells. Graft versus host disease is a reaction of the donor's immune
cells against the patient's body. Itacitinib plus standard treatment may help prevent graft
versus host disease in patients who have received a donor stem cell transplantation.